Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F
December 12 2005 - 8:02AM
PR Newswire (US)
WESTMINSTER, Colo., Dec. 12 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation
of new findings from its Phase 3 clinical trial of the
investigational radiation sensitizer EFAPROXYN(TM) (efaproxiral) in
patients with brain metastases. Preliminary data from the Phase 3
study, called REACH, were first announced in April 2003. Charles
Scott, Ph.D., CBS Squared, presented the findings in a poster
presentation Saturday at the 28th Annual San Antonio Breast Cancer
Symposium. In abstract #4040, titled "Improved Survival, Quality of
Life (QOL), and Quality-Adjusted Survival (QAS) in Breast Cancer
Patients Treated with Efaproxiral (EFAPROXYN(TM)) and Whole Brain
Radiation Therapy (WBRT) for Brain Metastases," Dr. Scott presented
a QAS analysis of data from the Company's Phase 3 REACH study,
which compared the survival benefit of brain metastases patients
receiving EFAPROXYN with WBRT to those receiving WBRT alone.
Results of the analysis indicated that the addition of EFAPROXYN to
WBRT led to a statistically significant increase in survival for
EFAPROXYN-arm patients with brain metastases originating from
breast cancer, which was accompanied by a statistically significant
improvement in both QOL and QAS, a composite measure of quality and
duration of survival. Specifically, EFAPROXYN-arm patients with
brain metastases originating from breast cancer experienced a
slower overall decline in Spitzer Quality of Life Index (SQLI)
scores over time (p
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024